BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11438565)

  • 1. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses.
    Griffith TS; Kawakita M; Tian J; Ritchey J; Tartaglia J; Sehgal I; Thompson TC; Zhao W; Ratliff TL
    J Natl Cancer Inst; 2001 Jul; 93(13):998-1007. PubMed ID: 11438565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
    Kawakita M; Rao GS; Ritchey JK; Ornstein DK; Hudson MA; Tartaglia J; Paoletti E; Humphrey PA; Harmon TJ; Ratliff TL
    J Natl Cancer Inst; 1997 Mar; 89(6):428-36. PubMed ID: 9091644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model.
    Siemens DR; Austin JC; Hedican SP; Tartaglia J; Ratliff TL
    J Natl Cancer Inst; 2000 Mar; 92(5):403-12. PubMed ID: 10699070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors.
    Elzey BD; Siemens DR; Ratliff TL; Lubaroff DM
    Int J Cancer; 2001 Dec; 94(6):842-9. PubMed ID: 11745487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.
    Grant JF; Iwasawa T; Sinn HW; Siemens DR; Griffith TS; Takacs EB; Ratliff TL
    Int J Cancer; 2006 Dec; 119(11):2632-41. PubMed ID: 16991124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector.
    Ghose A; Iakhnina E; Spaner D; Tartaglia J; Berinstein NL
    Hum Gene Ther; 2000 Jun; 11(9):1289-301. PubMed ID: 10890739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity.
    Puisieux I; Odin L; Poujol D; Moingeon P; Tartaglia J; Cox W; Favrot M
    Hum Gene Ther; 1998 Nov; 9(17):2481-92. PubMed ID: 9853515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
    Odin L; Favrot M; Poujol D; Michot JP; Moingeon P; Tartaglia J; Puisieux I
    Cancer Gene Ther; 2001 Feb; 8(2):87-98. PubMed ID: 11263530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Poxvirus vectors for gene transfer].
    Kawakita M; Yoshida O; Ratliff TL
    Hinyokika Kiyo; 1997 Nov; 43(11):835-8. PubMed ID: 9436032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells.
    Schroten C; Scheffer R; Boon L; de Ridder CM; Bangma CH; Kraaij R
    J Immunother; 2012; 35(2):125-30. PubMed ID: 22306900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
    Hodge JW; McLaughlin JP; Kantor JA; Schlom J
    Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
    Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
    Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
    Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
    Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver CD4-CD8- NK1.1+ TCR alpha beta intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro.
    Pied S; Roland J; Louise A; Voegtle D; Soulard V; Mazier D; Cazenave PA
    J Immunol; 2000 Feb; 164(3):1463-9. PubMed ID: 10640763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
    Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
    Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse NK1.1+ cytotoxic T cells can be generated by IL-2 exposure from lymphocytes which express an intermediate level of T cell receptor.
    Ikarashi Y; Maruoka H; Shinohara K; Sugimura T; Terada M; Wakasugi H
    Immunol Lett; 1998 Apr; 61(2-3):165-73. PubMed ID: 9657270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium.
    Yuhua L; Kunyuan G; Hui C; Yongmei X; Chaoyang S; Xun T; Daming R
    Int J Cancer; 2001 Nov; 94(3):438-43. PubMed ID: 11745427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.